RAPT Therapeutics, Inc. ( NASDAQ: RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria October 20, 2025 8:30 AM EDT Good morning, and welcome to RAPT's conference ...

Health officials have confirmed three cases of a new, more dangerous strain of mpox in California, raising concerns about its ...

Rapt Therapeutics said a mid-stage trial of its drug for chronic spontaneous urticaria, a skin condition that causes recurrent, spontaneous hives, showed comparable efficacy and safety to omalizumab, ...

RAPT Therapeutics ( ($RAPT) ) just unveiled an update. On October 20, 2025, RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Co., Ltd.

CRMD, CELC, RANI, and RAPT are pushing aggressively to the upside on Monday. Here's what is driving these four biotech stocks ...

RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing - Efficacy sustained at Week 16 after a single dose of RPT904 - Well tolerated with no serious ...

Peanut allergies in U.S. babies are on the decline! Early introduction guidelines are helping little ones build tolerance—and ...

Investing.com -- RAPT Therapeutics Inc (NASDAQ:RAPT) stock surged 56.3% in premarket trading Monday following the announcement of positive topline data from a Phase 2 trial of its RPT904 treatment for ...

Rapt stock surged Monday after the biotech company said its experimental hives treatment topped Roche's Xolair in a 16-week ...

The Trump administration is exploring ways to pay air traffic controllers while the federal government is shut down, ...

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Cycle ...

Peanuts represent one of the most common causes of immunoglobulin E (IgE)-mediated, or anaphylactic, food allergies in children, yet a landmark study found that early introduction of peanut to infants ...